Science Corp. Raises $230 Million for Its PRIMA Implant
Science Corp. has raised $230 million to accelerate the commercialisation of its PRIMA implant, a brain-computer interface for restoring sight.
Science Corp. has recently completed a $230 million funding round, bringing the company's post-money valuation to $1.5 billion. The investment aims to support the commercialisation of the PRIMA device, a retinal implant designed to restore sight in patients with advanced macular degeneration.
Funding Details
The funding round was led by Lightspeed Venture Partners and Khosla Ventures, with participation from Y Combinator, IQT and Quiet Capital. With this investment, Science Corp. has raised a total of about $490 million since its start in 2021. The capital will be used to accelerate the commercialisation of PRIMA and to expand the company's research, manufacturing and operational infrastructure.
The PRIMA Device
PRIMA is a retinal implant which, combined with camera-equipped glasses, aims to restore sight in patients with advanced macular degeneration. In clinical studies, the device has shown promising results, with 80% of patients achieving significant improvements in visual acuity, managing to read letters, numbers and words. This represents significant progress in treating blindness caused by degenerative retinal diseases.
Future Outlook
Science Corp. expects to obtain CE marking for PRIMA in the European Union by mid-2026, with the intention of launching the product in Germany, which offers established pathways for early access to new medical technologies. In the United States, the company is currently in discussions with the FDA to obtain the necessary approval. In addition, Science Corp. is expanding PRIMA's clinical trial programme to include inherited retinal diseases such as Stargardt disease and retinitis pigmentosa, with the aim of widening the treatment to a broader patient population.
Implications for the Brain-Computer Interface Sector
Science Corp.'s success highlights growing interest and investment in the brain-computer interface (BCI) sector. With competitors such as Elon Musk's Neuralink, which has raised a total of $1.85 billion, the industry is going through a phase of rapid evolution and development. Science Corp.'s approach of using less invasive retinal implants could accelerate the adoption of these technologies, offering therapeutic solutions for a range of neurological and sensory conditions.
Conclusion
- Science Corp. has raised $230 million to accelerate the commercialisation of its PRIMA implant, a device for restoring sight in patients with advanced macular degeneration.
- The device has shown promising results in clinical studies, with 80% of patients achieving significant improvements in visual acuity.
- Science Corp. expects CE marking for PRIMA in the European Union by mid-2026 and is in discussions with the FDA for US approval.
- Science Corp.'s less invasive approach using retinal implants could accelerate the adoption of brain-computer interfaces in treating neurological and sensory conditions.
- Science Corp.'s success highlights growing interest and investment in the brain-computer interface sector, with potential applications across a wide range of medical conditions.